SeekingAlpha · Mar 6, 2026
AL
NASDAQ · ALEC
Alector, Inc.
Healthcare · Biotechnology
$1.99
Down-$0.18 (-9.05%)
Updated Oct 6, 2026, 11:26 PM
SID Score
3.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 265.24M
- P/E ratio
- -1.75
- Dividend yield
- 0.00%
- 52-week range
- $1.37 – $2.76
- Volume
- 89.98M
- Avg. volume
- 1.15M
Price performance · ALEC
ALEC price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
ALEC closed at $1.99 after 20 trading sessions, down 19.43% for the selected period.
- Last close
- $1.99
- Period change
- -19.43%
- Period low
- $1.81
- Period high
- $2.47
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $2.725 | $2.73 | $1.96 | $1.99 | 89.98M |
| Oct 2, 2026 | $1.89 | $1.965 | $1.80 | $1.81 | 1.17M |
| Oct 1, 2026 | $1.82 | $1.91 | $1.805 | $1.86 | 774.59K |
| Sep 30, 2026 | $1.88 | $1.9491 | $1.83 | $1.85 | 792.7K |
| Sep 29, 2026 | $1.95 | $1.95 | $1.86 | $1.87 | 960.74K |
| Sep 28, 2026 | $1.92 | $1.955 | $1.86 | $1.92 | 713.34K |
| Sep 25, 2026 | $1.92 | $2.05 | $1.90 | $1.95 | 1.02M |
| Sep 24, 2026 | $2.02 | $2.05 | $1.905 | $1.92 | 849.55K |
| Sep 23, 2026 | $2.00 | $2.02 | $1.95 | $2.02 | 1.18M |
| Sep 22, 2026 | $1.97 | $2.035 | $1.93 | $2.01 | 1.46M |
| Sep 21, 2026 | $1.90 | $1.945 | $1.85 | $1.93 | 1.28M |
| Sep 18, 2026 | $1.85 | $1.91 | $1.79 | $1.91 | 2.12M |
| Sep 17, 2026 | $1.96 | $1.97 | $1.83 | $1.85 | 931.24K |
| Sep 16, 2026 | $2.06 | $2.06 | $1.91 | $1.925 | 622.26K |
| Sep 15, 2026 | $2.19 | $2.209 | $1.985 | $2.035 | 715.91K |
| Sep 14, 2026 | $2.15 | $2.225 | $2.095 | $2.21 | 2.47M |
| Sep 11, 2026 | $2.17 | $2.22 | $2.02 | $2.14 | 4.7M |
| Sep 10, 2026 | $2.22 | $2.24 | $2.00 | $2.14 | 3.78M |
| Sep 9, 2026 | $2.47 | $2.47 | $2.25 | $2.27 | 505.8K |
| Sep 8, 2026 | $2.38 | $2.61 | $2.33 | $2.47 | 916.85K |
Latest ALEC news
The latest Smart Investors Daily articles mentioning ALEC.
Stock researchCompany · Overview
Company
Market Activity
Research & News
ALEC research
Overview
Company profile and research snapshot.
Company profile
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $3.25
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 15, 2026 | Cantor Fitzgerald | Overweight | — |
| Mar 10, 2026 | BTIG | Buy | — |
| Oct 22, 2025 | Cantor Fitzgerald | Neutral | — |
| Oct 22, 2025 | TD Cowen | Hold | — |
| Oct 22, 2025 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Feb 25, 2026
Alector Q4 Earnings Assessment
Benzinga · Feb 25, 2026
Alector Q4 EPS $(0.34) Beats $(0.39) Estimate, Sales $6.237M Beat $2.672M Estimate
Alector (NASDAQ:ALEC) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.39) by 13.71 percent. This is a 1600 percent decrease over losses of $(0.02) per share from the same
Yahoo · Jan 20, 2026
Looking At The Narrative For Alector (ALEC) After Latozinemab Setback And Cost Cuts
The fair value estimate for Alector has shifted slightly, moving from 2.05 to 2.10, while the discount rate has also adjusted from 7.54% to 7.39%, even as the revenue growth assumption remains anchored to about a 50.08% decline. This reflects a recalibrated view after mixed Street research, where cautious ratings, the failed latozinemab Phase 3 trial, and a pipeline reset sit alongside cost cuts and remaining pipeline options that some investors still factor into their thinking. Continue with...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
